SPT-320

SPT-320
Clinical data
Other namesSPT320; LYT-320; LYT320
Routes of
administration		Oral[1]
Drug classMelatonin receptor agonist; Serotonin 5-HT2B receptor antagonist; Serotonin 5-HT2C receptor antagonist;

SPT-320, also formerly known as LYT-320, is a prodrug of agomelatine which is under development for the treatment of mood and anxiety disorders, for instance generalized anxiety disorder.[1][2]

As an agomelatine prodrug, it acts as a melatonin receptor agonist and as a serotonin 5-HT2B and 5-HT2C receptor antagonist.[1][2] The drug is taken by mouth and is said to bypass first-pass hepatic metabolism.[1][2]

As of December 2023, SPT-320 is in the preclinical research phase of development.[1][2] It is under development by Seaport Therapeutics and is being developed towards approval in the United States.[1][2] The chemical structure of SPT-320 does not yet appear to have been disclosed.[1]

References

  1. 1 2 3 4 5 6 7 "SPT-320 - Seaport Therapeutics". AdisInsight. 2 January 2024. Retrieved 14 January 2025.
  2. 1 2 3 4 5 "Delving into the Latest Updates on SPT-320 with Synapse". Synapse. 21 November 2024. Retrieved 14 January 2025. By leveraging Glyph, SPT-320 bypasses liver first-pass metabolism, allowing for lower dosing and reduced liver exposure.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.